Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Dr Jabbour expands on the FDA approval of ponatinib for patients with Ph-positive ALL, the agent’s mechanism of action, and data from the PhALLCON trial.